Latest Commercialization News

Sunshine Metals has extended gold mineralisation at its Sybil project in North Queensland, led by a 4-metre intersection grading 11.11g/t gold at Francis Creek. The company plans a further 2,600 metres of drilling from mid-October across existing and untested targets.

ReNerve’s October AGM presentation points to sharply higher sales, a growing US distribution network and a broader nerve repair pipeline. The company is also progressing a 240-patient NervAlign clinical study while relying on a $5 million RiverFort funding facility to support expansion.

Optiscan Imaging has lodged a US FDA 510(k) application for InVue, its precision surgery device designed to provide cellular-level imaging during operations. The submission moves the technology into formal regulatory review, but clearance and commercialisation remain uncertain.

Radiopharm says the FDA has provided a clear framework for the pivotal development of RAD101, its investigational brain metastases imaging agent. The company is preparing for Phase 3 while awaiting formal meeting minutes that could still refine the trial design and regulatory requirements.

Aurora Labs has appointed Andrew Garth as chief executive, moving former CEO Rebekah Letheby into a newly focused chief operating role. The reshuffle is intended to separate commercial strategy from technical execution as the company pursues scaled manufacturing and defence opportunities.

FlexiRoam has onboarded one of Australia’s four major banks to offer complimentary global data roaming on premium rewards Mastercard cards. The live program is expected to generate about USD 140,000 a year under management’s current planning case, although there is no minimum revenue commitment.

IODM has secured the first 15 university commitments in its planned 283-university US rollout, while revenue rose 10.2% despite a sharp fall in UK international student visa applications. The onboarding is not yet revenue, but the December-quarter target gives investors a clear execution test.

AdAlta and Shanghai Cell Therapy Group have approved the FDA briefing pack and manufacturing transfer plan for EW-001, bringing the mesothelioma CAR-T therapy closer to an Australian Phase 1 trial. The FDA meeting is scheduled for November, while two Chinese patients remain under follow-up, including a second complete responder.

CSL has secured an exclusive agreement to co-develop and co-promote Alentis Therapeutics’ investigational drug lixudebart, committing US$355 million upfront and funding a multi-trial development programme. The antibody remains unapproved, with its commercial potential dependent on results from ongoing and planned clinical studies.

First Graphene has signed a three-year agreement with Turkish manufacturer Aeropreg to develop and potentially commercialise PureGRAPH-enhanced carbon fibre prepreg. The partnership offers a clearer route into aerospace, defence and automotive supply chains, but commercial launch remains dependent on trial results.

HealthCo Healthcare and Wellness REIT has signed binding agreements for new leases covering its remaining 10 Healthscope hospitals, subject to final approvals. The resolution allows HCW to reinstate quarterly distributions while reducing its largest tenant concentration from 57% to 31%.

Brazilian Critical Minerals has signed binding agreements to acquire 90% of a Brazilian magnesium sulphate producer, aiming to secure a key input for its Ema rare earth project. The strategy offers greater supply-chain control, but the plant requires restructuring and carries estimated legacy liabilities of R$15.3 million.